Immunological evidence for hypochlorite-modified proteins in human kidney

American Journal of Pathology

Volumn 150, Issue 2, 1997, Pages 603-615

  Malle, Ernst ^a   Woenckhaus, Christian ^b   Waeg, Georg ^a   Esterbauer, Hermann ^a   Gröne, Elisabeth F ^b   Gröne, Hermann Josef ^b  

^a UNIVERSITY OF GRAZ   (Austria)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; EPITOPE; HYPOCHLORITE; LOW DENSITY LIPOPROTEIN; MONOCLONAL ANTIBODY; MYELOPEROXIDASE;

ARTICLE; ATHEROSCLEROSIS; DENSITOMETRY; FIBROSING ALVEOLITIS; FOAM CELL; GLOMERULOSCLEROSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY PARENCHYMA; NEPHROSCLEROSIS; OXIDATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

ADULT; AGED; BLOTTING, WESTERN; FEMALE; HUMANS; HYPOCHLOROUS ACID; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY DISEASES; KIDNEY GLOMERULUS; KIDNEY TUBULES; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PEROXIDASE; PROTEINS; SERUM ALBUMIN;

EID: 0031024294     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Cochrane CG: Cellular injury by oxidants, Am J Med 1991, 91:23S-30S
2. Steinbrecher UP, Zhang H, Lougheed M: Role of oxidatively modified LDL in atherosclerosis. Free Radical Biol Med 1990, 9:155-168
3. Berliner JA, Heinecke JW: The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996, 20: 707-727
4. Haberland ME, Steinbrecher U: Modified low-density lipoproteins: diversity and biological relevance to atherogenesis. Monogr Hum Genet 1992, 14:35-61
5. Haberland ME, Fong D, Cheng L: Malondialdehydealtered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 1988, 241:215- 218
6. Boyd HC, Gown AM, Wolfbauer G, Chait A: Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol 1989, 135:815-825
7. Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL: Low density lipoprotein undergoes oxidative modification In vivo. Proc Natl Acad Sci USA 1989, 86:1372-1376
8. Rosenfeld ME, Palinski W, Ylä-Herttuala S, Butler S, Witztum JL: Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 1990, 10:336-349
9. Rosenfeld ME, Khoo JC, Miller E. Parthasarathy S, Palinski W, Witztum JL: Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of lowdensity lipoproteins, and contain oxidation-specific lipid-protein adducts. J Clin Invest 1991, 87:90-99
10. Jürgens G, Chen Q, Esterbauer H, Mair S, Ledinski G, Dinges HP: Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B and apoprotein(a), Arterioscler Thromb 1993, 13:1689-1699
11. Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, Collen D: Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 1995, 95:2611-2619
12. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssönen K, Palinski W, Witztum JL: Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992, 339: 883-887
13. Kotani K, Maekawa M, Kanno T, Kondo A, Toda N, Manabe M: Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum, Biochim Biophys Acta 1994, 1215:121-125
14. Gröne EF, Walli AK, Gröne HJ, Miller B, Seidel D: The role of lipids in nephrosclerosis and glomerulosclerosis, Atherosclerosis 1994, 107:1-13
15. Keane W: Lipids and the kidney. Kidney Int 1994, 46: 910-920
16. Van Goor H, Fidler J, Weening J, Grond J: Determinants of focal and segmental glomerulosclerosis in the rat after renal ablation: evidence for involvement of macrophages and lipids, Lab Invest 1991, 64:754-765
17. Diamond JR, Karnovsky MJ: Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 1988, 33:917-924
18. Magil AB, Frohlich JJ, Innis SM, Steinbrecher UP: Oxidized low-density lipoprotein in experimental focal glomerulosclerosis. Kidney Int 1993, 43:1243-1250
19. Neale TJ, Ojha PP, Exner M, Poczewski H, Rüger B, Witzum JL, Davis P, Kerjaschki D: Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen. J Clin Invest 1994, 94:1577-1584
20. Wheeler DC, Ghana RS, Topley N, Petersen MM, Davies M, Williams JD: Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury, Kidney Int 1994, 45:1628-1636
21. Laurent B, Ardaillou R: Reactive oxygen species: production and role in the kidney. Am J Physiol 1986, 251:F765-F776
22. 2-halide system in immune complex nephritis. Kidney Int 1987, 32:342-349
23. Johnson RJ, Couser WG, Chi EY, Adler S, Klebanoff SJ: New mechanisms for glomerular injury: myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest 1987, 79:1379-1387
24. Johnson RJ, Guggenheim SJ, Klebanoff SJ, Ochi RF, Wass A, Baker P, Schulze M, Couser WG: Morphologic correlates of glomerular oxidant injury induced by the myeloperoxidase-hydrogen peroxide-halide system of the neutrophil. Lab Invest 1988, 58:294-301
25. 2-chloride system. Am J Pathol 1993, 143:907-917
26. Halliwell B, Gutteride JMCF: Role of free radicals and catolytic metal ions in human disease: an overview. Methods Enzymol 1990, 186:1-85
27. Weiss SJ, LoBuglio AF: Phagocyte-generated oxygen metabolites and cellular injury, Lab Invest 1982, 47: 5-18
28. Yamada T, Grisham MB: Role of neutrophil-derived oxidants in the pathogenesis of intestinal inflammation. Klin Wochenschr 1991, 69:988-994
29. Winterbourn CC: Comparative reactivities of various biological compounds with myeloperoxidase-hydrogen peroxide-chloride, and similarity of the oxidant to hypochlorite. Biochim Biophys Acta 1985, 840:204- 210
30. Hazell LJ, Stocker R: Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. Biochem J 1993, 290:165-172
31. O'Connell AM, Gieseg SP, Stanley KK: Hypochlorite oxidation causes cross-linking of Lp(a), Biochim Biophys Acta 1994, 1225:180-186
32. Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R: Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 1996, 97:1535-1544
33. Malle E, Hazell L, Stocker R, Sattler W, Esterbauer H, Waeg G: Immunologie detection and measurement of hypochlorite-modified LDL with specific monoclonal antibodies, Arterioscler Thromb Vase Biol 1995, 15: 982-989
34. Hazell LJ, van den Berg JJM, Stocker R: Oxidation of low-density lipoprotein by hypochlorite causes aggregation that is mediated by modification of lysine residues rather than lipid oxidation. Biochem J 1994, 302: 297-304
35. Gröne HJ, Weber K, Gröne E, Helmchen U, Osborn M: Coexpression of keratin and vimentin in damaged and regenerating tubular epithelia of the kidney. Am J Pathol 1987, 129:1-8
36. Springall DR, Hacker GW, Grimelius L, Polak JM: The potential of the immunogold-silver staining method for paraffin sections. Histochemistry 1994, 81:603-608
37. Malle E, Ibovnik A, Steinmetz A, Kostner GM, Sattler W: Identification of glycoprotein IIb as the lipoprotein(a)binding protein on platelets. Arterioscler Thromb 1994, 14:345-352
38. Gröne HJ, Walli A, Gröne E, Niedmann P, Thiery J, Seidel D, Helmchen U: Induction of glomerulosclerosis by dietary lipids: a functional and morphologic study in the rat. Lab Invest 1989, 60:433-446
39. Gröne HJ, Walli AK, Gröne E, Krämer A, Clemens MR, Seidel D: Receptor mediated uptake of apo B and apo E rich lipoproteins by human glomerular epithelial cells, Kidney Int 1990, 37:1449-1459
40. Gröne EF, Abboud HE, Höhne M, Walli AK, Gröne HJ, Stüker D, Robenek H, Wieland E, Seidel D: Actions of lipoproteins in cultured human mesanglal cells: modulation by mitogenic vasoconstrictors, Am J Physiol 1992 263:F686-F696
41. Gupta S, Rifici V, Crowley S, Brownlee M, Shan Z, Schlondorff D: Interactions of LDL and modified LDL with mesangial cells and matrix, Kidney Int 1992, 41: 1161-1169
42. Van Goor H, Ding G, Kees-Folts D, Grond J, Schreiner GF, Diamond JR: Biology of disease: macrophages and renal disease. Lab Invest 1994, 71:456-464
43. Keane WF, O'Donnell MP, Kasiske BL, Kim Y: Oxidative modification of low-density lipoproteins by mesangiat cells. J Am Soc Nephrol 1993, 4:187-194
44. Lee HS, Koh HI: Visualization of binding and uptake of oxidized low density lipoproteins by cultured mesangial cells, Lab Invest 1994, 71:200-208
45. Coritsidis G, Rifici V, Gupta S, Rie J, Shan Z, Neugarten J, Schlondorff D: Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells In vitro. Kidney Int 1991, 39:858-866
46. Maggi E, Bellazani R, Gazo A, Seccia M, Bellomo G: Autoantibodies against oxidatively-modified LDL in uremie patients undergoing dialysis. Kidney Int 1994, 46:869-876
47. Maggi E, Bellazani R, Falaschi F, Frattoni A, Perani G, Finardi G, Gazo A, Nai M, .Romanini D, Bellomo G: Enhanced LDL oxidation in uremie patients: additional mechanism for accelerated atherosclerosis? Kidney Int 1994, 45:876-883
48. Sutherland WH, Walker RJ, Ball MJ, Stapley SA, Robertson MC: Oxidation of low density lipoproteins from patients with renal failure or renal transplants. Kidney Int 1995, 48:227-236
49. Savenkova MI, Mueller DM, Heinecke JW: Tyrolyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J Biol Chem 1994, 269:20394- 20400
50. Daugherty A, Dunn JL, Rateri DL, Heinecke JW: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994, 94:437-444
51. Vissers MCM, Winterbourn CC, Hunt JS: Degradation of glomerular basement membrane by human neutrophils in vitro. Biochim Biophys Acta 1984, 804:154-160
52. Vissers MCM, Winterbourn CC: The effect of oxidants on neutrophil-mediated degradation of glomerular basement membrane collagen. Biochim Biophys Acta 1986, 889:277-286
53. Adler S, Baker PJ, Johnsen RJ, Ochi RF, Pritzl P, Couser WG: Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured mesangiai cells. J Clin Invest 1986, 77: 762-767
54. Hillegass LM, Griswold DE, Brickson B, AlbrightsonWinslow C: Assessment of myeloperoxidase activity in whole rat kidney. J Pharmacol Methods 1990, 24:285- 295
55. Laight DW, Lad N, Woodward B, Waterfall JF: Assessment of myeloperoxidase activity in renal tissue after ischaemia/reperfusion. Eur J Pharmacol 1994, 292: 81-88
56. Schierwagen C, Bylund-Fellius AC, Lundberg C: Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activity. J Pharmacol Methods 1984, 23:179-186
57. Ruiz-Torres P, Gonzaies-Rubio M, Lucio-Canzana FJ, Ruiz-Villaespesa A, Rodriguez-Puyol M, RodriguezPuyol D: Reactive oxygen species and platelet-activating factor synthesis in age related glomerulosclerosis. J Lab Clin Med 1994, 124:489-495
58. Janssen YM, van Houten B, Borm PJ, Mossman BT: Cell and tissue responses to oxidative damage. Lab Invest 1993, 69:261-274
59. Niwa Y, Kasatna T, Miyachi YS, Kanoh T: Neutrophil chemotaxis, phagocytosis and parameters of reactive oxygen species in human aging: cross-sectional and longitudinal studies. Life Sci 1989, 44:1655-1664
60. Rovin BH, Wurst E, Kohan DE: Production of reactive oxygen species by tubular epithelial cells in culture. Kidney Int 1990, 37:1509-1514
61. Ong ACM, Moorhead JF: Tubular lipidosis: epiphenomenon or pathogenetic lesion in human renal disease? Kidney Int 1994, 45:753-762